Feb 21, 2025 · Psoriasis is a skin disease that causes a rash with itchy, scaly patches, most commonly on the knees, elbows, trunk and scalp. Psoriasis is a common, long-term (chronic) disease with no cure. It can be painful, interfere with sleep and make it hard to concentrate.

Psoriasis is a skin disorder that causes skin cells to multiply up to 10 times faster than normal. This makes the skin build up into bumpy patches. They can grow anywhere, but most appear...

Apr 11, 2024 · There are a few types of psoriasis. While some are similar, they can have different symptoms and treatments. Each type affects a different area of your body. Knowing which kind of psoriasis you...

Psoriasis is a chronic inflammatory skin condition characterised by clearly defined, red and scaly plaques. It is classified into several types. Who gets psoriasis? Psoriasis affects 2–4% of males and females. It can start at any age including childhood, with onset peaks at …

Feb 1, 2024 · Psoriasis causes symptoms such as scaly, dry, or itchy skin. There’s no cure, but certain lifestyle changes and medications can help. You can also try to track and identify your …

Apr 22, 2025 · Psoriasis is a skin disease that causes red, scaly skin that may feel painful, swollen, or hot. Learn more about the types and what causes psoriasis.

Find in-depth information about psoriasis, discover key strategies to help you cope with the chronic skin condition, and understand the ten questions that you should ask your doctor.

Psoriasis (suh-rye-ah-sis) is a condition that causes the body to make new skin cells in days rather than weeks. As these cells pile up on the surface of the skin, you may see thick, scaly patches. Plaque psoriasis is the most common type of psoriasis

What is psoriasis? This condition develops when the body makes skin cells too quickly, causing skin cells to pile up and form visible patches or spots on the skin. Is psoriasis contagious?

Apr 25, 2025 · Adults with moderate/severe plaque psoriasis of at least 6 months' duration were randomized to two high-dose regimens of risankizumab (Skyrizi), administered three times over 16 weeks. The primary ...